Revolution Medicines Files 8-K
Ticker: RVMDW · Form: 8-K · Filed: Oct 23, 2024 · CIK: 1628171
| Field | Detail |
|---|---|
| Company | Revolution Medicines, Inc. (RVMDW) |
| Form Type | 8-K |
| Filed Date | Oct 23, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
Related Tickers: REVMD
TL;DR
REVMD filed an 8-K on 10/23/24, no major news, just routine disclosure.
AI Summary
On October 23, 2024, Revolution Medicines, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is not reporting on a specific material event that requires immediate disclosure. The company is incorporated in Delaware and its principal executive offices are located in Redwood City, California.
Why It Matters
This 8-K filing indicates that Revolution Medicines, Inc. is making a routine disclosure. Investors should review the filing for any specific details that may be relevant to the company's operations or strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material events or significant financial changes.
Key Players & Entities
- Revolution Medicines, Inc. (company) — Registrant
- October 23, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Redwood City, California (location) — Principal Executive Offices
FAQ
What is the purpose of this 8-K filing by Revolution Medicines, Inc.?
The 8-K filing is a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating that the company is reporting under "Other Events" as of October 23, 2024.
When was this 8-K report filed?
The 8-K report was filed on October 23, 2024.
Where are Revolution Medicines, Inc.'s principal executive offices located?
The principal executive offices of Revolution Medicines, Inc. are located at 700 Saginaw Drive, Redwood City, California, 94063.
In which state is Revolution Medicines, Inc. incorporated?
Revolution Medicines, Inc. is incorporated in Delaware.
What is the Commission File Number for Revolution Medicines, Inc.?
The Commission File Number for Revolution Medicines, Inc. is 001-39219.
Filing Stats: 1,858 words · 7 min read · ~6 pages · Grade level 12 · Accepted 2024-10-23 06:05:02
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RVMD The Nasdaq
Filing Documents
- d750511d8k.htm (8-K) — 66KB
- g750511g00p19.jpg (GRAPHIC) — 124KB
- g750511g00p20.jpg (GRAPHIC) — 100KB
- g750511g00p21.jpg (GRAPHIC) — 101KB
- 0001193125-24-241397.txt ( ) — 1001KB
- rvmdw-20241023.xsd (EX-101.SCH) — 4KB
- rvmdw-20241023_def.xml (EX-101.DEF) — 13KB
- rvmdw-20241023_lab.xml (EX-101.LAB) — 21KB
- rvmdw-20241023_pre.xml (EX-101.PRE) — 14KB
- d750511d8k_htm.xml (XML) — 5KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this report that are not historical facts may be considered "forward-looking statements," including, without limitation, statements regarding the potential advantages of RMC-6236, including potential safety, tolerability, efficacy and durability. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect" and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the Company's development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, the process of conducting clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the Company's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the Company's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on the Company's business of global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business o
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVOLUTION MEDICINES, INC. Date: October 23, 2024 By: /s/ Mark A. Goldsmith Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer